The Zebrafish Breathes New Life into the Study of Tuberculosis by Henna Myllymäki et al.
May 2016 | Volume 7 | Article 1961
Mini Review
published: 19 May 2016
doi: 10.3389/fimmu.2016.00196
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Jason Paul Gigley, 
University of Wyoming, USA
Reviewed by: 
Marc S. Dionne, 
Imperial College London, UK  
Philip Elks, 
University of Sheffield, UK
*Correspondence:
Henna Myllymäki  
henna.myllymaki@staff.uta.fi
Specialty section: 
This article was submitted 
to Microbial Immunology, 
a section of the journal 
Frontiers in Immunology
Received: 29 February 2016
Accepted: 06 May 2016
Published: 19 May 2016
Citation: 
Myllymäki H, Bäuerlein CA and 
Rämet M (2016) The Zebrafish 
Breathes New Life into the 
Study of Tuberculosis. 
Front. Immunol. 7:196. 
doi: 10.3389/fimmu.2016.00196
The Zebrafish Breathes new Life 
into the Study of Tuberculosis
 
Henna Myllymäki1*, Carina A. Bäuerlein1 and Mika Rämet1,2,3,4
1BioMediTech, University of Tampere, Tampere, Finland, 2Department of Pediatrics, Tampere University Hospital, Tampere, 
Finland, 3Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland, 4PEDEGO Research Unit, Medical 
Research Center Oulu, University of Oulu, Oulu, Finland
Tuberculosis (TB) is a global health emergency. Up to one-third of the world’s population 
is infected with Mycobacterium tuberculosis, and the pathogen continues to kill 1.5 mil-
lion people annually. Currently, the means for preventing, diagnosing, and treating TB are 
unsatisfactory. One of the main reasons for the poor progress in TB research has been 
a lack of good animal models to study the latency, dormancy, and reactivation of the 
disease. Although sophisticated in vitro and in silico methods suitable for TB research 
are constantly being developed, they cannot reproduce the complete vertebrate immune 
system and its interplay with pathogens and vaccines. However, the zebrafish has 
recently emerged as a useful alternative to more traditional models, such as mice, rab-
bits, guinea pigs, and non-human primates, for studying the complex pathophysiology of 
a mycobacterial infection. The model is based on the similarity between Mycobacterium 
marinum – a natural fish pathogen – and M. tuberculosis. In both zebrafish larvae and 
adult fish, an infection with M. marinum leads to the formation of macrophage aggre-
gates and granulomas, which resemble the M. tuberculosis infections in humans. In this 
review, we will summarize the current status of the zebrafish model in TB research and 
highlight the advantages of using zebrafish to dissect mycobacterial virulence strategies 
as well as the host immune responses elicited against them. In addition, we will discuss 
the possibilities of using the adult zebrafish model for studying latency, dormancy, and 
reactivation in a mycobacterial infection.
Keywords: tuberculosis, zebrafish model system, vaccination, Mycobacterium marinum, Mycobacterium 
tuberculosis, Mycobacterium infections, granuloma, latency
inTRODUCTiOn
Tuberculosis (TB) is still the world’s second deadliest infectious disease killing 1.5 million people and 
with an estimated 9.6 million new cases reported to the WHO in 2015 (1). An estimated one-third of 
the world’s population has been exposed to TB. 5–10% of these latent carriers will eventually develop 
the active disease (1).
The causative agent of TB, Mycobacterium tuberculosis, spreads through the air (Figure 1A). 
Alveolar macrophages phagocytose the inhaled mycobacteria and transport them into the lung 
tissues (2). A cascade of pro- and anti-inflammatory signaling leads to the recruitment and accu-
mulation of additional macrophages and other leukocytes in the pulmonary tissues. Eventually, 
the formation of granulomas, the hallmark of pathological TB, is initiated. The granuloma is 
a heterogeneous, but well-organized, and dynamic accumulation of immune cells, including 
FiGURe 1 | Granuloma formation in human Mycobacterium tuberculosis infection and in zebrafish M. marinum infection.  
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TABLe 1 | Characteristics of a mycobacterial infection in humans, adult zebrafish, and zebrafish embryos.
Human Adult zebrafish (>3 months) Zebrafish embryo (<6 days) Reference
immune system Innate and adaptive Innate and adaptive Innate only (6–8)
Mycobacterial pathogen Mycobacterium tuberculosis and atypical 
mycobacteria including Mycobacterium marinum
Mycobacterium marinum Mycobacterium marinum (9–11)
Natural susceptibility Yes Yes Yes (9, 10, 12)
Infection route and 
infectious dose
natural infection
Airways ID50 <10 bacilli Digestive tract ? (9, 10, 12)
experimental infection
N/A Multiple injection techniques, 
intraperitoneal injection is the most 
commonly used; <30–10,000 cfu
Multiple injection techniques, 
caudal injection is the most 
commonly used; <10–>300 cfu
(8, 13–15)
Infection phases Acute Acute Progressive? (10, 13–17)
Latent Latent
Reactivation Reactivation
Granuloma types Early Early Primitive? (4, 5, 
13–18)Fibrous Fibrous
Necrotic Necrotic
Cell types involved in 
granuloma formation
Macrophages Macrophages Macrophages (4, 5, 
13–18)Neutrophils Neutrophils Neutrophils
Dendritic cells Dendritic cells Epithelial cells
Lymphocytes (T cells, B cells, and NK cells) Lymphocytes (T cells and B cells)
Fibroblasts Epithelial cells
Epithelial cells
(A) M. tuberculosis spreads as an aerosol, and first infects alveolar macrophages. In most individuals, the infection is maintained in a latent, subclinical state, which 
is characterized by the formation of granulomas (left). The mature granulomas have a caseous, necrotic core, surrounded by infected macrophages and 
lymphocytes. Upon reactivation, the granulomas are disrupted, causing cavities in the lungs. The mycobacteria escape from the granulomas and are disseminated 
in cough droplets, which facilitates the transmission of the disease. (B) Upon infection with M. marinum, the granulomas in the zebrafish embryo develop within a 
few days and mainly consist of infected and uninfected macrophages and recruited neutrophils. (C) Depending on the bacterial dose, the adult zebrafish  
M. marinum infection can lead to a latent or an active, progressive disease. A latent infection is characterized by the formation of granulomas in various organs. As 
the early granulomas mature, their inner parts become caseous and surrounded by a fibrous wall. The zebrafish with a latent infection remain asymptomatic. A (re)
activated, progressive mycobacterial infection is characterized by the disruption of the granulomatous structures, rapid replication and dissemination of 
mycobacteria and profound tissue damage. Eventually, a progressive mycobacterial disease will lead to death in most fish. The zebrafish granulomas were visualized 
with Ziehl–Neelsen staining, mycobacteria are seen as purple rods. cfu, colony-forming unit.
FiGURe 1 | Continued
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blood-derived infected and uninfected macrophages, foamy 
macrophages, and epithelioid cells (3). The inner cell mass 
is usually surrounded by a ring of leukocytes and fibroblasts 
(4) (Figure 1A; Table 1). The localization and control of the 
bacteria and the restriction of the immune response to a 
defined area are generally regarded as the main functions of 
granulomas (5).
Mycobacteria can persist asymptomatic within the granuloma 
for decades. However, a dysregulation of the immune system can 
reactivate the mycobacteria, which leads to disease progression 
(secondary TB) (2) (Figure  1A) Primary TB mainly occurs in 
children, who are at the highest risk for TB meningitis and a dis-
seminated form of the disease (19).
Efforts to eradicate TB are obstructed by the lack of unambigu-
ous diagnostic tools, the lengthy antibiotic treatments required 
for curation, the growing problem of multi-drug-resistant 
bacteria, and the poor protection provided by the Bacillus 
Calmette–Guérin (BCG), the only vaccine available (1). As a 
live vaccine, BCG imposes a risk of a disseminated infection in 
immunocompromised patients (1, 20, 21). Thus, there is a need 
to develop new effective drugs and vaccines against TB. For this 
purpose, relevant animal models are essential. The most com-
monly used animal models in TB research are mice, guinea pigs, 
and non-human primates (NHP), all of which have their limita-
tions related to either space, costs, ethical aspects, or their ability 
to replicate the human disease pathology (22, 23). Recently, the 
zebrafish–M. marinum model has gained popularity as a natural 
pathogen–host system that closely recapitulates the pathology of 
human TB (Table 1) (13, 23). The infection model and its applica-
tions are discussed in more detail below.
THe ZeBRAFiSH–MYCOBACTERIUM 
MARINUM inFeCTiOn MODeL
Mycobacterium marinum, the causative agent of fish mycobac-
teriosis, is a close relative of M. tuberculosis (24). M. marinum 
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spreads via water, and it also occasionally infects humans, but 
the infection is usually limited to the skin (fish tank granu-
loma) (11). Thus, M. marinum is safer to work with and has a 
shorter replication time than M. tuberculosis (9, 23). Similar to 
human TB, fish mycobacteriosis displays an acute and chronic 
form and the subsequently formed granulomas also resemble 
the lesions caused by M. tuberculosis [Figure 1 (13–15)]. Both 
bacteria are able to survive and replicate within macrophages 
(23, 25). In a laboratory setting, the zebrafish is an advanta-
geous choice as a host organism for M. marinum for several 
reasons: multiple infection techniques can be used for both 
zebrafish embryos and adults (26); for a review, see Ref. (8, 
27–29) (Figures 1B,C). The transparency of the embryos allows 
the use of sophisticated in vivo real-time imaging techniques, 
including multiple leukocyte and macrophage fluorescent 
reporter lines (30–32), and several techniques for genetic 
manipulation (6, 33–35). Moreover, zebrafish are small in size, 
and produce numerous offspring, making them also suitable 
for large-scale screening studies, including drug screens (6). 
Despite the anatomical differences between fish and mammals, 
the zebrafish is a vertebrate model with an innate and adap-
tive immunity consisting of the same primary components as 
present in humans (6, 36, 37). As zebrafish lack lymph nodes, 
immune cells mainly develop and perform their functions in 
the spleen, the kidney, and the thymus (6, 38, 39). Zebrafish 
embryos rely solely on innate immunity. In the embryos, 
functional macrophages and neutrophils emerge 1 and 2 days 
post-fertilization (dpf), respectively, while lymphocytes start 
developing after 4 dpf and the adaptive immunity becomes fully 
functional at 4  weeks post-fertilization (wpf) (7). This facili-
tates studying the function of the innate and adaptive immune 
system, as well as different cell types, separately (8, 33).
HOST–MYCOBACTERIUM 
inTeRACTiOnS – inSiGHTS inTO  
eARLY inFeCTiOn evenTS FROM  
ZeBRAFiSH LARvAe
Zebrafish larvae have been especially useful in elucidating the 
role of macrophages and the strategies the phagocytosed myco-
bacteria use to suppress phagosomal maturation, apoptosis, and 
the antibacterial innate immune response (8, 25, 40). Scavenger 
receptors of different classes have been studied in the context 
of the phagocytosis of mycobacteria. For example, Marco binds 
the glycolipid trehalose 6,69-dimycolate on the mycobacterial 
cell wall and affects the regulation of the subsequent proinflam-
matory response (41). CD36 also appears to be involved in 
mycobacterial control, though its role and the regulation of its 
expression seem quite complicated (42). Following phagocyto-
sis, Toll-like receptor (TLR) signaling via MyD88 is needed for 
resistance against an early mycobacterial infection (43, 44). For 
example, the activation of the TLR signaling leads to the pro-
duction of antibacterial molecules by macrophages, such as the 
perforin Mpeg1.2 (45). In the zebrafish, the myd88−/− mutants 
have been a useful tool in elucidating the role of TLR signaling 
in mycobacterial resistance (46, 47).
Toll-like receptor signaling is involved in the initiation of the 
production of reactive oxygen and nitrogen species (ROS and 
RNS, respectively). In the zebrafish, early stabilization of the 
transcription factor hypoxia-inducible factor 1α (Hif-1α) in neu-
trophils limits bacterial growth by inducing iNOS, which in turn 
leads to increased protein nitrosylation (48). Later in the course 
of the infection, this response is decreased in the developing 
granulomas by a mechanism independent of the early secretory 
antigenic target 6 system 1/region of difference 1 (ESX-1/RD1) 
virulence locus (49).
As a mean to counteract the mycobacterial evasion strategies, 
the host can induce autophagy, a process which enables cells to 
digest their cytoplasmic contents, including microorganisms and 
membranous structures, in lysosomes (50). This is dependent 
on TLR signaling and Myd88, which are linked via the DNA 
damage-regulated autophagy modulator DRAM1. DRAM1 is 
needed for the formation of autophagosomes and for their fusion 
with lysosomes, while a DRAM1 deficiency leads to defects in 
maintaining the mycobacteria inside vesicles in macrophages 
and in the control of mycobacterial growth (51), Again, zebrafish 
larvae provide feasible tools for observing the events of autophagy 
in vivo and in real-time utilizing both light and electron micros-
copy, including the GFP-Lc3-transgenic line, for the visualization 
of autophagosomal structures (52).
ZeBRAFiSH LARvAe MODeL  
CHALLenGe OLD DOGMAS in  
MYCOBACTeRiAL ReSiSTAnCe
After a successful infection by mycobacteria, granulomas are 
seeded. The granulomas in zebrafish embryos mainly consist of 
aggregated macrophages, intra- and extracellular mycobacteria, 
together with recruited neutrophils, and form within a few days 
post-infection (18, 53); for a review, see Ref. (54). Despite their 
rather primitive structure, the embryonic zebrafish granulomas 
provide a physiological model for studying cellular processes 
affecting mycobacterial infections, such as the generation of 
hypoxia and angiogenesis. Injection of mycobacteria into the cau-
dal vein results in the development of non-hypoxic granulomas 
in the richly vascularized area of the caudal hematopoietic tissue 
(48). In contrast, granulomas resulting from a trunk infection 
reside in a sparsely vascularized area and can become hypoxic 
and induce vascularization (55).
Importantly, studies on early granulomas in zebrafish larvae 
have challenged some of the old dogmas. In general, granulomas 
have long been considered a protection mechanism elicited by the 
host. However, recent evidence from zebrafish embryos suggests 
that M. marinum uses the macrophages and granulomas for its own 
expansion and dissemination (16, 17). The bacteria can recruit 
new, uninfected macrophages to the granuloma site using the 
RD1 locus (16). The arriving macrophages phagocytize infected, 
dead cells and thus contribute to the spreading of the bacteria. 
The recruitment of new macrophages is enhanced by the bacteria 
by ESAT-6-mediated production of matrix metalloproteinase 9 
(17). Mycobacteria also need the RD1 locus for escaping from the 
phagosomes into the cytoplasm of infected macrophages both in 
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human cells and in zebrafish (51, 56). Additionally, mycobacteria 
use cell surface lipids to mask pathogen-associated molecular pat-
terns, hence selectively infect permissive macrophages and avoid 
microbicidal ones (57). Thus, granulomas present a combat zone 
for the host immune system and the bacterial response, rather 
than purely a protection mechanism of the host to prevent the 
spread of bacteria (4).
In addition to basic research, the zebrafish larvae provide a 
feasible tool for early-stage drug development and large-scale 
screens (33, 58, 59). Two major, and related, issues in improv-
ing the TB drug development are the lengthiness of the curative 
treatments and the increasing emergence of drug-resistant 
bacteria (1). Discoveries made in zebrafish larvae revealed that 
intracellular mycobacteria use their efflux pumps to acquire a 
tolerance against the antibiotics commonly used to treat human 
TB, which allows the bacteria to persist and replicate in the 
cytosol. M. tuberculosis uses the same mechanism (60). However, 
this tolerance was reversed by an efflux pump inhibitor, such as 
verapamil, which can therefore reduce the tolerance to antibiotics 
and thereby shorten treatment times (61). These results prove that 
the zebrafish larval model can replicate the function of antituber-
cular compounds (60). In addition, angiogenesis has been shown 
to be important for granuloma formation. Therefore, targeting 
vascularization, for example, by inhibiting vascular endothelial 
growth factor receptor (VEGFR) signaling could provide a means 
to target mycobacterial infections and inhibit mycobacterial dis-
semination, resembling the strategy used in cancer therapies (55).
On the host’s side, cytokines and their respective receptors 
play an important role in protection against mycobacteria. For 
example, the signaling axis mediated by chemokine CXC-motive 
containing receptor 3 (CXCR3) has been implicated in mycobac-
terial spreading and could thus provide a therapeutic target (62). 
In addition, in both humans and zebrafish larvae the leukotriene 
A4 hydrolase (LTA4H) locus controls pro- and anti-inflammatory 
mediators that in turn control the expression of TNF (63). While 
TNF is required for the host response against mycobacteria, its 
excess renders the host more susceptible to an infection, high-
lighting the importance of a balanced response (64). Thus, the 
zebrafish can elucidate the pathways controlling the host immune 
responses, and this information can be further applied to target-
ing these pathways with new drugs and developing host-directed 
therapies (8, 63–66). In addition, further investigation into the 
evasion strategies that mycobacteria use to interfere with the host 
defense mechanisms can potentially lead to the discovery of novel 
drug targets to combat mycobacterial diseases (49, 67).
MYCOBACTeRiAL LATenCY vS. 
ADAPTive iMMUniTY – THe ADULT 
ZeBRAFiSH AS A MODeL FOR TB
One of the main advantages of the zebrafish–M. marinum model 
may lie in granuloma formation, which has not been easy to repro-
duce in the traditional model animals (22). In the adult zebrafish, 
however, the histology of the mature granulomas resembles those 
seen in human TB with their caseous, necrotic core surrounded 
by leukocytes and epithelial cells (4, 17). Granulomas are found 
in various organs such as the pancreas, gonads, spleen, and liver 
several weeks post-infection (Figure 1C) (13–15).
The latency of TB is another aspect that has been difficult to 
replicate experimentally (22). As this is also challenging to study 
in humans, our knowledge of the required immunological mecha-
nisms for the control of a mycobacterial infection at its different 
stages remains limited (17). However, this could be improved 
by studying the zebrafish model, as like humans, adult zebrafish 
develop a latent, non-progressive disease with dormant bacteria 
residing within well-structured granulomas, and the fish remain 
asymptomatic (13, 14). Moreover, reactivation of the bacteria 
can occur spontaneously, or can be induced experimentally by 
an immune deficiency, such as exposure to γ-irradiation. In either 
case, reactivation will lead to the active spreading of the bacteria 
and the development of symptoms similar to an active infection 
as well as high lethality, much as in human TB (13).
Although the early cytokine response mediated by the innate 
immunity plays an important role in determining whether a 
mycobacterial infection leads to an acute or latent disease, the 
adaptive immunity is also required to control the bacteria. This 
is seen in the adult rag−/− zebrafish that are devoid of lympho-
cytes. The mutant fish are unable to generate a latent state of 
the infection and are, therefore, hypersusceptible to M. marinum 
(13,  14,  68). So far, the significance of different lymphocyte 
subsets has not been extensively studied in the zebrafish myco-
bacterial infection. Nevertheless, Th1 as well as Th2 cells seem 
to be involved in the effective control of mycobacterial infections 
(69, 70). Interestingly, a novel Th2-like subset of cells capable 
of inhibiting the growth of M. tuberculosis has been found in 
human TB patients. This observation challenges the old idea 
that only Th1 cells are important for mycobacterial control (71). 
Genetic differences in the mycobacterial strains also seem to 
affect their virulence, for example, strains isolated from infected 
humans more commonly causing an acute disease, and isolates 
from poikilothermic species causing a chronic infection in the 
zebrafish (72).
While the zebrafish larvae provide a feasible tool for screening 
for drugs against TB, the adult zebrafish appears to be a promis-
ing model for early vaccine development. The zebrafish can be 
partially protected against mycobacteriosis by BCG (68, 73) or 
attenuated M. marinum (74), suggesting the use of adult zebrafish 
as a model for studying the feasibility of conserved mycobacterial 
antigens as vaccines. For example, the RD1 virulence locus and 
the ESX-1 secretion system, which are absent from BCG, have 
been shown to be important for virulence in M. tuberculosis. In 
M. marinum, RD1 is also is also required for granuloma formation 
in both larvae and adult fish (14, 49, 75, 76). Indeed, the antigens 
in this region do show some potential as targets for vaccines in the 
zebrafish as well as in other models (68, 73, 77–79). The zebrafish 
can also provide a feasible model for searching for the most effec-
tive antigen combinations and for studying different vaccination 
strategies. For instance, a DNA-based vaccine consisting of three 
mycobacterial antigens (Ag85, ESAT-6, and CFP10), which has 
also been studied in other TB models, confers protection against 
mycobacteria in zebrafish (68, 80–82). Furthermore, the effect of 
BCG can be boosted by a DNA vaccine (68, 73, 80–82). Adult 
zebrafish could therefore be used for developing vaccines for 
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both replacing and boosting BCG, as well as for studying the 
immunological correlates required for protection.
DiSCUSSiOn
The lack of an animal model that recapitulates the human disease 
stages and pathology has in part hampered the development 
of new drugs, vaccines, and diagnostic tools against TB (22). 
Even though the mammalian animal models mostly used for 
TB research, namely, mice, rabbits, and guinea pigs, do develop 
granulomatous structures, only primates are a natural host for 
M. tuberculosis and show true latency and reactivation (83). 
However, the use of primates as laboratory animals is difficult in 
terms of ethical and economic issues as well as space limitations. 
When drug and vaccine development is considered, a natural 
host–pathogen pair is likely to be a more reliable model. Moreover, 
choosing to work with (zebra)fish might have an additional 
practical advantage: as mycobacterial infections are able to cause 
epidemics in fish farms, aquariums, and zebrafish facilities (9, 84), 
vaccinating fish against M. marinum is of potential economic and 
ecological relevance. This has been studied to some extent, for 
example, in the striped bass with the Ag85A DNA vaccine (85) 
and in the Japanese flounder with BCG (86). Thus, the results 
obtained in human biomedical research and veterinary studies 
could potentially augment each other.
The zebrafish–M. marinum infection exhibits essentially the 
same disease phases as those seen in human TB, including latency 
and reactivation  –  either spontaneously or following immuno-
suppression (13, 14). This might have important implications 
as the different disease phases probably also represent on the 
one hand different strategies of bacterial adaptation, and on the 
other hand, different stages of the host immune response (87). 
Since these aspects can be replicated in the zebrafish infection, 
the model should facilitate a more detailed dissection of both the 
effective (and deleterious) immune responses and the bacterial 
counter strategies in each stage of the infection. The zebrafish 
model can also be used to complement the human patient data in 
the identification of reliable biomarkers for the diagnosis of the 
different stages of TB (88).
Besides biomarkers, new drugs and vaccines are needed to 
combat TB. For this, a better knowledge concerning the correlates 
of a protective immune response is essential (89). The HI virus 
attacks CD4+ T cells, and a co-infection renders the patients 
highly susceptible to TB. Therefore, it seems that CD4+ T cells are 
important for the host response (90). This does not mean, however, 
that the study of other cell types should be neglected, as they too 
can reveal new immunological mechanisms (70, 71). Moreover, 
deficiencies in the IFN-γ signaling axis lead to hypersusceptibility 
toward TB, and thus IFN-γ expression has been associated with 
protection against the disease (90). However, despite inducing 
high levels of IFN-γ production, a promising vaccine candidate, 
MVA85A, failed recently to enhance protection in an efficacy trial 
(91). This suggests that it is unlikely that a single immunological 
factor could predict the course of a TB infection (90, 92). Thus, 
there are still gaps in our knowledge of how an effective host 
defense against TB is elicited, and relevant animal models are 
needed to fill in the missing information. Furthermore, once the 
picture of protection mechanisms is more complete, the animal 
models can aid us in translating this information into the benefit 
of clinical medicine. We believe the zebrafish will be an important 
player in fulfilling both of these tasks.
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